In-depth valuation analysis including DCF scenarios and peer comparisons.
AI Insight: Moderna’s current price far exceeds the high-confidence weighted fair value of $20.08, indicating a significant overvaluation risk with implied downside over 60%. The negative DCF mid estimate contrasts sharply with high analyst target midpoints, reflecting divergent views on future profitability amid poor profitability and growth scores. Despite strong liquidity and leverage scores, the absence of downside scenarios suggests price resilience but elevated valuation risk.